A research study of the role of chloroquine in treating patients with dengue

A randomised, double-blind, placebo-controlled trial of chloroquine for treatment of dengue

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN38002730

Enrollment

220

Registered

2006-11-21

Start date

2006-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue fever Infections and Infestations Viral haemorrhagic fevers

Interventions

Patients will receive placebo (starch) or 600 mg chloroquine on day one and two, then 300 mg on day three. Delivery is by oral ingestion.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any adult patient (either sex) with dengue who gives consent. We plan to enrol all patients with suspected dengue presenting within three days of illness onset.

Exclusion criteria

Exclusion criteria: No consent

Design outcomes

Primary

Measure	Time frame
The primary objective is to compare the antiviral efficacy of chloroquine in the treatment of dengue infections as assessed by negative Reverse Transcriptase (RT)-Polymerase Chain Reaction (PCR) detection of viral Ribonucleic Acid (RNA) in plasma and clearance of NS-1 from blood.	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Viet Nam

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026